



[001360] In any aspect or embodiment described herein, R^{14a} and R^{14b} together with the

carbon atom to which they are attached form , wherein R^{23} is selected from H, C_{1-4} alkyl, $-C(O)C_{1-4}$ alkyl. In any of the aspects or embodiments described herein, the ULM is of the formula:




or a pharmaceutically acceptable salt thereof, wherein R_1 , R_3 , R_{14a} , R_{14b} , and R_{15} of ULM-q and ULM-r are as described herein; and X is CH or N.

[001361] In any of the aspects or embodiments described herein, R_1 is C_{1-6} alkyl.

[001362] In any of the aspects or embodiments described herein, one of R_{14a} and R_{14b} is H, C_{1-6} alkyl, C_{1-6} haloalkyl, optionally substituted C_{1-4} alkylamine, C_{1-6} alkoxy, $(CH_2)_qC_{1-6}$ alkoxy, $(CH_2)_qC_{1-6}$ alkoxy- C_{3-7} heterocycloalkyl, $(CH_2)_qOH$, $(CH_2)_qNR_{27a}R_{27b}$, $(CH_2)_qNHCOC_{1-6}$ alkyl, C_{3-6} cycloalkyl, or $NR_{27a}R_{27b}$; each R_{26} is independently H, C_{1-6} alkyl or $NR_{27a}R_{27b}$; each R_{27a} and R_{27b} is independently H or C_{1-6} alkyl; and q is 1, 2, 3 or 4.

[001363] In any of the aspects or embodiments described herein, one of R_{14a} and R_{14b} is H, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, optionally substituted C_{1-4} alkylamine, $(CH_2)_qC_{1-6}$ alkoxy, $(CH_2)_qC_{1-6}$ alkoxy- C_{3-7} heterocycloalkyl, $(CH_2)_qOH$, $(CH_2)_qNR_{27a}R_{27b}$, $(CH_2)_qNHCOC_{1-6}$ alkyl, C_{3-6} cycloalkyl, or $NR_{27a}R_{27b}$; each R_{26} is independently H, C_{1-4} alkyl or $NR_{27a}R_{27b}$; each R_{27a} and R_{27b} is independently H or C_{1-4} alkyl; and q is 1 or 2.

[001364] In any of the aspects or embodiments described herein, R_{28} is C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{1-6} haloalkyl, $(CH_2)_qOC_{1-6}$ alkyl, $(CH_2)_qOH$, $(CH_2)_qNR_{27a}R_{27b}$, $(CH_2)_qNHCOC_{1-6}$ alkyl, or




R_{29} is H, C_{1-6} alkyl, $NR_{27a}R_{27b}$ or $(CH_2)_qNHCOC_{1-6}$ alkyl; and wherein q is 1 or 2.

CLAIMS

What Is Claimed Is:

1. A ~~bifunctional~~ compound having the chemical structure:



or a pharmaceutically acceptable salt thereof,

wherein:

- (a) ~~the L is a chemical linking moiety comprises a chemical structural unit represented by the formula:—(A^L)_q—~~, wherein:


(A^L)_q is a group which is connected to the ULM and the PTM;

~~q of the chemical linking moiety~~ is an integer ~~greater than or equal to 1 from 1 to 100;~~


each A^L is independently CR^{L1}R^{L2}, O, S, SO, SO₂, NR^{L3}, SO₂NR^{L3}, SONR^{L3}, CONR^{L3}, NR^{L3}CONR^{L4}, NR^{L3}SO₂NR^{L4}, CO, CR^{L1}=CR^{L2}, C≡C, SiR^{L1}R^{L2}, P(O)R^{L1}, P(O)OR^{L1}, NR^{L3}C(=NCN)NR^{L4}, NR^{L3}C(=NCN), NR^{L3}C(=CNO₂)NR^{L4}, C₃₋₁₁cycloalkyl optionally substituted with 1-6 groups independently selected from R^{L1} and R^{L2}, C₃₋₁₁heterocyclyl optionally substituted with 1-6 groups independently selected from R^{L1} and R^{L2}, aryl optionally substituted with 1-6 groups independently selected from R^{L1} and R^{L2}, or heteroaryl optionally substituted with 1-6 groups independently selected from R^{L1} and R^{L2}, where R^{L1} or R^{L2}, each independently are optionally linked to other groups to form cycloalkyl or heterocyclyl moiety, optionally substituted with 1-4 R^{L5} groups; and


R^{L1}, R^{L2}, R^{L3}, R^{L4} and R^{L5} are, each independently, H, halogen, C₁₋₈alkyl, OC₁₋₈alkyl, SC₁₋₈alkyl, NHC₁₋₈alkyl, N(C₁₋₈alkyl)₂, C₃₋₁₁cycloalkyl, aryl, heteroaryl, C₃₋₁₁heterocyclyl, OC₃₋₈cycloalkyl, SC₃₋₈cycloalkyl, NHC₃₋₈cycloalkyl, N(C₃₋₈cycloalkyl)₂, N(C₃₋₈cycloalkyl)(C₁₋₈alkyl), OH, NH₂, SH, SO₂C₁₋₈alkyl, CC-C₁₋₈alkyl, CCH, CH=CH(C₁₋₈alkyl), C(C₁₋₈alkyl)=CH(C₁₋₈alkyl), C(C₁₋₈alkyl)=C(C₁₋₈alkyl)₂, COC₁₋₈alkyl, CO₂H, CN, CF₃, CHF₂, CH₂F, NO₂, SF₅, SO₂NHC₁₋₈alkyl, SO₂N(C₁₋₈alkyl)₂, SONHC₁₋₈alkyl, SON(C₁₋₈alkyl)₂, CONHC₁₋₈alkyl, CON(C₁₋₈alkyl)₂, N(C₁₋₈alkyl)CONH(C₁₋₈alkyl), N(C₁₋₈alkyl)CON(C₁₋₈alkyl)₂, NHCONH(C₁₋₈alkyl), NHCON(C₁₋₈alkyl)₂, NHCONH₂, N(C₁₋₈alkyl)SO₂NH(C₁₋₈alkyl), N(C₁₋₈alkyl)SO₂N(C₁₋₈alkyl)₂, NH SO₂NH(C₁₋₈alkyl), NH SO₂N(C₁₋₈alkyl)₂, or NH SO₂NH₂;

(b) the ULM is ~~an E3 ubiquitin ligase binding moiety that binds a Von Hippel-Lindau E3 ubiquitin ligase and that is represented by the chemical structure:~~



wherein:

W³ is optionally substituted aryl, optionally substituted heteroaryl, or  ;
 R₉ and R₁₀ are independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted hydroxyalkyl, optionally substituted heteroaryl, or haloalkyl, or R₉, R₁₀, and the carbon atom to which they are attached form an optionally substituted cycloalkyl;
 R₁₁ is optionally substituted heterocyclyl, optionally substituted alkoxy, optionally



R₁₂ is H or optionally substituted alkyl;

R₁₃ is H, optionally substituted alkyl, optionally substituted alkylcarbonyl, optionally substituted (cycloalkyl)alkylcarbonyl, optionally substituted aralkylcarbonyl,

optionally substituted arylcarbonyl, optionally substituted (heterocyclyl)carbonyl, or optionally substituted aralkyl;

one of R_{14a} and R_{14b} ~~are each independently~~ is H, ~~amine~~amino, haloalkyl, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted hydroxyl alkyl, optionally substituted ~~alkylamine~~alkylamino, optionally substituted heteroalkyl, optionally substituted alkyl-heterocycloalkyl, optionally substituted alkoxy-heterocycloalkyl, COR_{26} , $CONR_{27a}R_{27b}$, $NHCOR_{26}$, or $NHCH_3COR_{26}$; and the other of R_{14a} and R_{14b} is H; or R_{14a} and R_{14b} together with the carbon atom to which they are attached form an optionally substituted 3 to 5 membered cycloalkyl, heterocycloalkyl, spirocycloalkyl, or spiroheterocyclyl, wherein the spiroheterocyclyl is not ~~epoxide-epoxy~~ or ~~aziridine~~aziridinyl;

W^5 is optionally substituted phenyl, optionally substituted naphthyl, or an optionally substituted 5-10 membered heteroaryl;

R_{15} is H, halogen, CN, OH, NO_2 , $NR_{27a}R_{27b}$, OR_{27a} , $CONR_{27a}R_{27b}$, $NR_{27a}COR_{27b}$, $SO_2NR_{27a}R_{27b}$, $NR_{27a}SO_2R_{27b}$, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted haloalkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted heterocyclyl;

each R_{16} is independently halogen, CN, optionally substituted alkyl, optionally substituted haloalkyl, hydroxy, or optionally substituted haloalkoxy;

o is 0, 1, 2, 3, or 4;

each R_{18} is independently H, halogen, optionally substituted alkoxy, cyano, optionally substituted alkyl, haloalkyl, or haloalkoxy;


each R_{26} is independently H, optionally substituted alkyl, or $NR_{27a}R_{27b}$;

each R_{27a} and R_{27b} is independently H, optionally substituted alkyl, or R_{27a} and R_{27b} together with the nitrogen atom to which they are attached form a 4-6 membered heterocyclyl;

p is 0, 1, 2, 3, or 4; and

 indicates the site of attachment of ~~the~~ L; and

(c) the PTM is ~~a SMARCA2 protein targeting moiety having a chemical structure represented by Formula I or III:~~



wherein:


is the attachment point to L;

W_{PTM1} is a phenyl substituted with a hydroxy substituent and optionally substituted with 1 or 2 substituents independently selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, amino, phosphate, alkylamino, and cyano;

W_{PTM2} is pyridazinyl optionally substituted with an amino group;

W_{PTM3} is an optionally substituted 5–6-membered heteroaryl, an optionally substituted 4-9 cycloalkyl, an optionally substituted 4-9 membered heterocyclyl, an optionally substituted bridged bicycloalkyl, or an optionally substituted bridged biheterocyclyl, preferably an optionally substituted pyrazole, pyrrole, imidazole, oxazole, oxadiazole, or triazole;

W_{PTM5} is an optionally substituted 5–6-membered aryl or an optionally substituted 5–6-membered heteroaryl; or





wherein:

is the attachment point to L;

W_{PTM1} is a phenyl substituted with a hydroxy substituent and optionally substituted with 1 or 2 substituents independently selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, amino, phosphate, alkylamino, and cyano;

W_{PTM2} is a pyridazinyl substituted with an amino group; and

W_{PTM6} and W_{PTM7} are a spirocyclic ring system with a structure selected from:



wherein:

W_{PTM1} is an optionally substituted 5- or 6-membered aryl or an optionally substituted 5- or 6-membered heteroaryl, wherein the optional substitutions of W_{PTM1} are 1, 2, or 3 substituents independently selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, amino, phosphate, alkylamino, and cyano;

W_{PTM2} is an optionally substituted 5- or 6-membered aryl or an optionally substituted 5- or 6-membered heteroaryl, wherein the optional substitutions of W_{PTM2} are 1, 2, or 3 substituents independently selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, amino, alkylamino, and cyano;

W_{PTM3} is absent, an optionally substituted 5- or 6-membered aryl, an optionally substituted 5- or 6-membered heteroaryl, an optionally substituted 4-9 membered cycloalkyl, an optionally substituted 4-9 membered heterocyclyl, an optionally substituted bridged bicycloalkyl, or an optionally substituted bridged biheterocyclyl, wherein the optional substitutions of W_{PTM3} are 1 or 2 substituents independently selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, amino, alkylamino, and cyano;


~~W_{PTM5} is absent, an optionally substituted 5- or 6-membered aryl, an optionally substituted 5- or 6-membered cycloalkyl, or an optionally substituted 5- or 6-membered heterocycle, wherein the optional substitutions of W_{PTM5} are 1 or 2 substituents independently selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, amino, alkylamino, and cyano;~~

~~W_{PTM6} and W_{PTM7} are independently an optionally substituted 4-7 membered cycloalkyl or an optionally substituted 4-7 membered heterocyclyl, wherein the optional substitutions of W_{PTM6} and W_{PTM7} are 1 or 2 substituents independently selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, amino, alkylamino, and cyano, wherein the rings of W_{PTM6} and W_{PTM7} are fused or linked via a spiro connection; and~~

~~ is the attachment point to the chemical linking moiety.~~

2. The compound according to claim 1, wherein the PTM is ~~represented by Formula~~

I:



~~or a pharmaceutically acceptable salt thereof, wherein:~~

~~W_{PTM1} is an optionally substituted phenyl or a pyridyl;~~


~~W_{PTM2} is an optionally substituted 6-membered heteroaryl;~~

~~W_{PTM3} is absent, an optionally substituted 5- or 6-membered heteroaryl, an optionally substituted 4-9 membered cycloalkyl, an optionally substituted 4-9 membered heterocyclyl, an optionally substituted bridged bicycloalkyl, or an optionally substituted bridged biheterocyclyl;~~

~~W_{PTM5} is absent, an optionally substituted 5- or 6-membered aryl, or an optionally substituted 5- or 6-membered heteroaryl.~~

3. The compound according to claim 2, wherein W_{PTM3} is an optionally substituted pyrazolyl, pyrrolyl, imidazolyl, oxazolyl, oxadiazolyl, or triazolyl.

~~3.4.~~ The compound according to claim 2, wherein the PTM is ~~represented by the~~ formula:




~~or a pharmaceutically acceptable salt thereof, wherein:~~

~~W_{PTM3} is absent, an optionally substituted 5- or 6-membered heteroaryl, an optionally substituted 4-9 membered cycloalkyl, an optionally substituted 4-9 membered heterocyclyl, an optionally substituted bridged bicycloalkyl, or an optionally substituted bridged biheterocyclyl; and~~


~~W_{PTM5} is an optionally substituted 5- or 6-membered aryl or an optionally substituted 5- or 6-membered heteroaryl.~~

~~4.5.~~ The compound according to claim ~~34~~, wherein the PTM is ~~represented by the~~ formula:




~~or a pharmaceutically acceptable salt thereof, wherein: W_{PTM5} is phenyl, pyridinepyridinyl, pyrimidinepyrimidinyl, or pyrazinepyrazinyl.~~

~~5.6.~~ The compound according to claim 1, wherein the PTM is ~~represented by the~~ formula:



or a pharmaceutically acceptable salt thereof.

6.7. The compound according to claim 1, wherein the PTM is represented by Formula III:




or a pharmaceutically acceptable salt thereof, wherein:


W_{PTM1} is a phenyl substituted with a hydroxy substituent and optionally substituted with 1 or 2 substituents independently selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, amino, phosphate, alkylamino, and cyano;


W_{PTM2} is a pyridazine substituted with amino group; and


W_{PTM6} and W_{PTM7} are a spirocyclic ring system with a structure selected from:



78. The compound according to ~~any one of claims 1-6~~claim 1, wherein the PTM is selected from the group consisting of:







89. The compound according to claim 1, wherein the ULM ~~has a chemical structure~~ selected from is:

R_{14a} is H, haloalkyl, optionally substituted alkyl, methyl, fluoromethyl, hydroxymethyl, ethyl, or isopropyl; ~~and R_{14b} is hydrogen; or R_{14a} and R_{14b}, together with the carbon atom to which they are attached form a cyclopropyl;~~

R₁₅ is H, halogen, CN, OH, NO₂, optionally substituted heteroaryl, optionally substituted aryl; optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted haloalkoxy, optionally substituted cycloalkyl, or optionally substituted heterocyclyl;


X is ~~C~~, CH₂, or C=O;

R₃ is ~~absent or~~ an optionally substituted 5- or 6-membered heteroaryl; and



indicates the site of attachment of the chemical linker group.

910. The compound ~~of~~ according to claim 1, wherein the ULM is ~~of the formula:~~



or a pharmaceutically acceptable salt thereof, wherein:

R₁ is H, optionally substituted alkyl, or optionally substituted cycloalkyl;

R₃ is ~~an~~ optionally substituted 5- or 6-membered heteroaryl;

~~R₃ is absent or an optionally substituted 5- or 6-membered heteroaryl;~~

W⁵ is optionally substituted phenyl, optionally substituted naphthyl, or optionally substituted pyridinyl;

one of R_{14a} or R_{14b} is H, optionally substituted alkyl, haloalkyl, optionally substituted alkoxy, optionally substituted hydroxyl alkyl, optionally substituted ~~alkylamine~~alkylamino, optionally substituted heteroalkyl, optionally substituted alkyl-heterocycloalkyl, optionally substituted alkoxy-heterocycloalkyl, COR₂₆, CONR_{27a}R_{27b}, NHCOR₂₆, or NHCH₃COR₂₆; and the other of R_{14a} or R_{14b} is H; or R_{14a} and R_{14b}, together with the carbon atom to which they are attached, form an optionally substituted 3 to 5 membered cycloalkyl,

~~epoxide~~-epoxy or ~~aziridine~~aziridinyl;

R_{15} is CN, fluoroalkyl, , , , , , , or optionally substituted ;

each R₁₆ is independently halogen, CN, optionally substituted alkyl, optionally substituted haloalkyl, hydroxy, or haloalkoxy;

each R₂₆ is independently H, optionally substituted alkyl, or NR_{27a}R_{27b};

each R_{27a} and R_{27b} is independently H, optionally substituted alkyl, or R_{27a} and R_{27b} together with the nitrogen atom to which they are attached form a 4-6 membered heterocyclyl;


R₂₈ is H, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted heteroalkyl, optionally substituted ~~alkylamine~~alkylamino, optionally substituted hydroxyalkyl, ~~amine~~amino, optionally substituted alkynyl, or optionally substituted cycloalkyl;

α is 0, 1, or 2; and

 and  indicates the site of attachment of the chemical linker group.

11. The compound according to claim 10, wherein R₁₅ is  or , wherein R_{28a} is halogen, optionally substituted alkyl, or fluoroalkyl.

1012. The compound according to ~~claim 1~~, wherein the ULM is ~~of the formula:~~



wherein:





R₃ is ~~absent or~~ an optionally substituted 5- or 6-membered heteroaryl;

each of X⁴, X⁵, and X⁶ is ~~independently selected from~~ CH ~~and or~~ N, wherein no more than 2 are N;


R¹ is C₁₋₆ alkyl;

one of R^{14a} or R^{14b} is H, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkoxy, optionally substituted hydroxyl alkyl, optionally substituted ~~alkylamine~~alkylamino, optionally substituted heteroalkyl, optionally substituted alkyl-heterocycloalkyl, optionally substituted alkoxy-heterocycloalkyl, COR²⁶, CONR^{27a}R^{27b}, NHCOR²⁶, or NHCH₃COR²⁶; and the other of R^{14a} or R^{14b} is H; or R^{14a} and R^{14b}, together with the carbon atom to which they are attached, form an optionally substituted 3 to 5 membered cycloalkyl, heterocycloalkyl, spirocycloalkyl or spiroheterocyclyl, wherein the spiroheterocyclyl is not ~~epoxide-epoxy~~ or ~~aziridine~~aziridinyl;

each R_{27a} and R_{27b} is independently H or C₁₋₆ alkyl;

R¹⁵ is, , , , , or CN;

R²⁸ is H, methyl, CH₂N(Me)₂, CH₂OH, CH₂O(C₁₋₄alkyl), CH₂NHC(O)C₁₋₄alkyl, NH₂,



R^{28C} is H, methyl, fluoro, or chloro;

R¹⁶ is H, C₁₋₄ alkyl, fluoro, chloro, CN, or C₁₋₄alkoxy; and




indicates the site of attachment of the chemical linker group.

~~1113~~. The compound ~~according to~~claim 1012, wherein:


one of R^{14a} or R^{14b} ~~are selected from~~is H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ hydroxyalkyl, C₁₋₄ alkyloxyalkyl, C₁₋₄ alkyl-NR_{27a}R_{27b} and CONR_{27a}R_{27b}; and the other of R^{14a} or R^{14b} is H; or

R^{14a} and R^{14b}, together with the carbon atom to which they are attached form a ~~C₂~~C₃₋₄ cycloalkyl.

~~1214~~. The compound according to ~~claim 10 or 11~~ claim 12 or 13, wherein R^{14a} and R^{14b}

together with the carbon atom to which they are attached, form , wherein R²³ is selected from H, C₁₋₄alkyl, and -C(O)C₁₋₄alkyl.

~~1315~~. The compound according to ~~claim 10~~ claim 12, wherein the ULM is ~~of the formula:~~



~~or a pharmaceutically acceptable salt thereof~~, wherein:

X⁴ is CH or N, and



indicates the site of attachment of the chemical linker group.

~~1416~~. The compound according to ~~claim 10 or 131~~, ~~or a pharmaceutically acceptable salt thereof~~, wherein R₁ is C₁₋₆ alkyl.

~~1517~~. The compound according to any one of claims ~~10, 13, or 1412, 15, or 16~~, ~~or a pharmaceutically acceptable salt thereof~~, wherein:

one of R^{14a} or R^{14b} is H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, optionally substitute C₁₋₄ alkylamine~~alkylamino~~, C₁₋₆ alkoxy, (CH₂)_qC₁₋₆ alkoxy, (CH₂)_qC₁₋₆ alkoxy-C₃₋₇ heterocycloalkyl, (CH₂)_qOH, (CH₂)_qNR_{27a}R_{27b}, or (CH₂)_qNHCOC₁₋₆ alkyl, ~~or NR_{27a}R_{27b}~~; and the other of R^{14a} or R^{14b} is H; or R^{14a} and R^{14b}, together with the carbon atom to which they are attached form C_{3-6.5} cycloalkyl;

each R₂₆ is independently H, C₁₋₆ alkyl, or NR_{27a}R_{27b};

each R_{27a} and R_{27b} is independently H or C₁₋₆ alkyl; and

q of the ~~VLM-ULM~~ is 1, 2, 3, or 4.

~~1618.~~ The compound ~~according to~~ any one of claims ~~10, 13, or 14~~ 12, 15, or 16, or a ~~pharmaceutically acceptable salt thereof~~, wherein:

one of R_{14a} or R_{14b} is H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, optionally substituted C₁₋₄ ~~alkylamine~~alkylamino, (CH₂)_qC₁₋₆ alkoxy, (CH₂)_qC₁₋₆ alkoxy-C₃₋₇ heterocycloalkyl, (CH₂)_qOH, (CH₂)_qNR_{27a}R_{27b}, or (CH₂)_qNHCOC₁₋₆ alkyl, ~~or NR_{27a}R_{27b}~~; and the other of R^{14a} or R^{14b} is H; R^{14a} and R^{14b}, together with the carbon atom to which they are attached form C₃₋₆₅ cycloalkyl;


each R₂₆ is independently H, C₁₋₄ alkyl or NR_{27a}R_{27b};

each R_{27a} and R_{27b} is independently H or C₁₋₄ alkyl; and

q of the ~~VLM-ULM~~ is 1 or 2.

~~1719.~~ The compound ~~according to~~ ~~any one of claims 9~~ claim 10, or a ~~pharmaceutically acceptable salt thereof~~, wherein:

R₂₈ is C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₆ haloalkyl, (CH₂)_qOC₁₋₆alkyl, (CH₂)_qOH, (CH₂)_qNR_{27a}R_{27b},




R₂₉ is H, C₁₋₆ alkyl, NR_{27a}R_{27b} or (CH₂)_qNHCOC₁₋₆ alkyl; and

q of the ~~VLM-ULM~~ is 1 or 2.

~~1820.~~ The compound ~~according to~~ claim ~~10~~ 12, or a ~~pharmaceutically acceptable salt thereof~~, wherein R³ is isoxazolyl, 4-chloroisoxazolyl, 4-fluoroisoxazolyl, or pyrazolyl.

~~1921.~~ The compound ~~according to~~ claim ~~18~~ 20, or a ~~pharmaceutically acceptable salt thereof~~, wherein X⁴ is CH.

~~2022.~~ The compound ~~according to~~ claim ~~18 or 19~~ 1, wherein the ULM ~~has the formula~~ is:



salt thereof,

wherein:


R^1 is C_{1-6} alkyl;

X^4 is CH or N;

R_{30} is H, F, or Cl;


R^{16} is H, C_{1-4} alkyl, fluoro, chloro, CN, or C_{1-4} alkoxy; and

R_{28} is H, methyl, $CH_2N(Me)_2$, CH_2OH , $CH_2O(C_{1-4}alkyl)$, $CH_2NHC(O)C_{1-4}alkyl$, NH_2 ,





indicates the site of attachment of L.



2123. The compound according to claim 2022, wherein the ULM has the formula is:









or a pharmaceutically acceptable salt thereof, wherein R_{30} is H, F, or Cl, and  indicates the site of attachment of L.


2224. The compound according to any one of claims 1, 10, 13, and 21 claim 1, wherein the ULM is a ULM as provided in a compound selected from:
















































































































































wherein  indicates the site of attachment of L.




(1),




(2),




(3),




(4),




(5),




(6),




(7),




(8),




(9),




(10),




(11),




(12),




(13),




(14),




(15),




(16),




(17),




(18),




(19),




(20),




(21),




(22),




(23),




(24),




(25),




(26),




(27),




(28),




(29),




(30),




(31),




(32),




(33),




(34),




(35),




(36),




(37),




(38),




(39),




(40),




(41),




(42),




(43),




(44),




(45),




(46),




(47),




(48),




(49),




(50),




(51),




(52),




(53),




(54),




(55),




(56),



(57),




(58),




(59),









(71),




(72),




(73),




(74),




(75),




(76),




(77),




(78),




(79),




(80),




(81),




(82),




(83),




(84),




(85),




(86),




(87),




(88),




(89),




(90),




(91),




(92),




(93),




(94),




(95),




(96),




(97),




(98),




(99),




(100),




(101),




(102),




(103),




(104),




(105),




(106),




(107),









(108),




(109),




(110),


~~(111),~~~~(112),~~~~(113),~~~~(114),~~~~(115),~~~~(116),~~




(117),




(118),




(119),




(120),




(121),




(122),




(123),




(124),




(125),




(126),




(127),




(128),




(129),




(130),




(131),




(132),




(133),




(134),




(135),




(136),




(137),




(138),




(139),




(140),




(141),




(142),



(143),




(144),




(145),







(151),




(152),




(153),




(154),




(155),




(156),




(157),




(158),




(159),




(160),




(161),




(162),




(163),




(164),




(165),




(166),




(167),




(168),



(169),




(170),




(171),







(178),




(179),




(180),




(181),




(182),




(183),




(184),




(185),



(186),










(187),




(188),




~~(195),~~~~(196),~~~~(197),~~~~(198),~~~~(199),~~~~(200),~~




(201),




(202),




(203),




(204),




(205),




(206),




(207),




(208),




(209),




(210),




(211),




(212),




(213),




(214),





(215),




(216),




(217),







(223),




(224),




(225),




(226),




(227),




(228),




(229),




(230),




(231),




(232),




(233),




(234),




(235),




(236),




(237),




(238),




(239),




(240),




(241),






(242),





(243),




(244),







~~(245),~~~~(246),~~


~~(247),~~

~~(248),~~


~~(249),~~

~~(250),~~


~~(251),~~~~(252),~~~~(253),~~~~(254),~~~~(255),~~~~(256),~~




(257),




(258),




(259),




(260),




(261),




(262),




(263),




(264),




(265),




(266),




(267),




(268),




(269),




(270),




(271),







(272),




(273),




(274),

~~(275),~~~~(276),~~~~(277),~~


~~(278),~~




~~(279),~~




(280),




(281),




(282),




(283),




(284),




(285),




(286),




(287),




(288),




(289),




(290),




(291),




(292),




(293),




(294),




(295),




(296),




(297),




(298),




(299),




(300),




(301),




(302),




(303),




(304),




(305),




(306),




(307),




(308),




(309),




(310),




(311),




(312),




(313),




(314),




(315),




(316),




(317),




(318),




(319),




(320),



(321),




(322),




(323),









(335),




(336),



(337),




(338),




(339),







(345),




(346),




(347),




(348),




(349),




(350),




(351),




(352),




(353),




(354),




(355),




(356),




(357),




(358),




(359),




(360),




(361),




(362),




(363),




(364),




(365),




(366),




(367),




(368),




(369),




(370),




(371),




(372),




(373),




(374),




(375),




(376),




(377),




(378),




(379),




(380),




(381),




(382),




(383),




(384),




(385),




(386),



(387),




(388),




(389),







(394),




(395),




(396),




(397),




(398),




(399),




(400),




(401),




(402),




(403),




(404),




(405),




(406),




(407),




(408),




(409),




(410),




(411),




(412),




(413),




(414),




(415),




(416),




(417),




(418),




(419),




(420),




(421),




(422),




(423),




(424),




(425),




(426),




(427),




(428),




(429),




(430),




(431),




(432),




(433),




(434),




(435),




(436),




(437),




(438),




(439),




(440),




(441),




(442),




(443),




(444),




(445),




(446),




(447),





(448),





(449),




(450),

~~(451),~~


~~(452),~~

~~(453),~~


~~(454),~~




~~(455),~~




(456),




(457),




(458),




(459),




(460),




(461),



(462),




(463),




(464),







(469),




(470),




(471),




(472),




(473),




(474),




(475),




(476),




(477),




(478),




(479),




(480),




(481),




(482),




(483),




(484),




(485),




(486),




(487),




(488),




(489),




(490),




(491),




(492),




(493),




(494),




(495),




(496),




(497),




(498),




(499),




(500),




(501),




(502),




(503),




(504),




(505),




(506),







(507),




(508),




(509),


~~(510),~~~~(511),~~~~(512),~~~~(513),~~




(514),



(515),




(516),




(517),









(526),




(527),




(528),




(529),




(530),




(531),



(532),




(533),




(534),

and




(535).

25. The compound according to any one of claims 1 to 24, wherein L is:



or



wherein:

W^{L1} and W^{L2} are each independently aryl, heteroaryl, cyclic, heterocyclyl, C_{1-6} alkyl, bicyclic, biaryl, biheteroaryl, or -biheterocyclyl, each optionally substituted with R^Q , each R^Q is independently a H, halo, OH, CN, CF_3 , hydroxyl, nitro, $C\equiv CH$, C_{2-6} alkenyl, C_{2-6} alkynyl, optionally substituted linear or branched C_1-C_6 alkyl, optionally substituted linear or branched C_1-C_6 alkoxy, optionally substituted linear or branched OC_{1-3} alkyl, OH, NH_2 , $NR^{Y1}R^{Y2}$, CN;

or 2 R^Q groups taken together with the atom they are attached to, form a 4-8 membered ring system containing 0-4 heteroatoms;

Y^{L1} is each independently a bond, NR^{YL1} , O, S, NR^{YL2} , $CR^{YL1}R^{YL2}$, C=O, C=S, SO, SO_2 , optionally substituted linear or branched C_1-C_6 alkyl and optionally one or more C atoms are replaced with O, or optionally substituted linear or branched C_1-C_6 alkoxy;

Q^L is a 3-6 membered alicyclic or aromatic ring with 0-4 heteroatoms, optionally bridged, optionally substituted with 1-6 R^Q , each R^Q is independently H, optionally substituted linear or branched C_1-6 alkyl optionally substituted by 1 or more halo or C_1-6 alkoxyl;

or 2 R^Q groups taken together with the atom they are attached to, form a 3-8 membered ring system containing 0-2 heteroatoms;

R^{YL1} , R^{YL2} are each independently H, OH, optionally substituted linear or branched C_{1-6} alkyl optionally substituted by 1 or more halogen or C_{1-6} alkoxyl;

or R^1 , R^2 together with the atom they are attached to, form a 3-8 membered ring system containing 0-2 heteroatoms;


n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and




indicates the attachment point to the PTM or ULM moieties.




23. —The compound of any of claims 1, 10, 13, and 21, wherein:
each A^{L1} is independently $CR^{L1}R^{L2}$, O , NR^{L3} , $CONR^{L3}$, $NR^{L3}CONR^{L4}$, CO , $CR^{L1}=CR^{L2}$, $C\equiv C$,
 C_{3-11} cycloalkyl optionally substituted with 1-6 groups independently selected from R^{L1} and
 R^{L2} , C_{3-11} heterocyclyl optionally substituted with 1-6 groups independently selected from
 R^{L1} and R^{L2} , aryl optionally substituted with 1-6 groups independently selected from R^{L1}
and R^{L2} , or heteroaryl optionally substituted with 1-6 groups independently selected from
 R^{L1} and R^{L2} , where R^{L1} or R^{L2} , each independently are optionally linked to other groups to
form cycloalkyl and/or heterocyclyl moiety, optionally substituted with 1-4 R^{L5} -groups;
and
 R^{L1} , R^{L2} , R^{L3} , R^{L4} and R^{L5} are, each independently, H, halogen, C_{1-8} alkyl, OC_{1-8} alkyl,
 NHC_{1-8} alkyl, $N(C_{1-8}$ alkyl) $_2$, C_{3-11} cycloalkyl, aryl, heteroaryl, C_{3-11} heterocyclyl, OH, NH_2 , SH,
 CCH , COC_{1-8} alkyl, CO_2H , CN, CF_3 , CHF_2 , CH_2F , or NO_2 .

2426. The compound according to any one of claims 1 to 24, wherein the chemical linking moiety has a structure selected from L is selected from:










, wherein each m, n, o, p, q, r, s, and t of the chemical linking moiety is independently selected from 0, 1, 2, 3, and 4.






2527. The compound according to any one of claims 1 to 24, wherein the chemical linking moiety is selected from L is selected from:















26. ~~The compound of claim 2, wherein W_{PTM3} is an optionally substituted pyrazole, pyrrole, imidazole, oxazole, oxadiazole, or triazole.~~







27. ~~The compound of claim 3, wherein W_{PTM5} is an optionally substituted pyridine, pyrimidine, or pyrazine.~~






28. The compound according to claim 1, wherein the compound is selected from a member selected from compounds 1-151, 156-176, 178-427, 429-488, 490-514, and 517-535:













































































































































































































































































































































































































































































































































































;

29. — ~~The compound of claim 28, wherein the compound has a $D_{\max}$ for SMARCA2 that is greater than or equal to 80%.~~

~~3029.~~ A pharmaceutical composition comprising ~~an effective amount of a bifunctional a~~ compound according to ~~any of~~ claims 1, and a pharmaceutically acceptable carrier.

~~3130.~~ The pharmaceutical composition according to ~~claim~~ ~~3029~~, wherein the composition further comprises ~~at least one of an~~ additional bioactive agent ~~or another compound of claim 1.~~

~~3231.~~ The pharmaceutical composition according to ~~of~~ claim ~~3130~~, wherein the additional bioactive agent is anti-cancer agent.

~~33. — A therapeutically effective amount of at least one compound of claim 1 for use in a treatment of a disease or disorder or ameliorating at least one symptom of the disease or disorder.~~

~~3432.~~ A pharmaceutical composition comprising a pharmaceutically acceptable carrier and ~~an effective amount of at least one a~~ compound according to ~~of~~ claim 1 for use in treating a ~~disease or disorder or ameliorating at least one symptom of the disease or disorder~~ cancer.

~~35. The composition of claim 33 or 34, wherein the disease or disorder is associated with SMARCA1, BRAHMA or BRM accumulation and aggregation.~~


~~36. The composition of claim 35, wherein the disease or disorder is cancer.~~

~~3733. The pharmaceutical composition according to~~ claim ~~3632~~, wherein the cancer is a SWI/SNF associated cancer or a cancer with a SMARCA4 mutation.

~~3834. The pharmaceutical composition according to~~ ~~of~~ claim ~~3733~~, wherein the SWI/SNF associated cancer or the cancer with a SMARCA4 mutation is lung cancer or non-small cell lung cancer.

~~3935. The pharmaceutical composition according to~~ ~~of~~ claim ~~3632~~, wherein the cancer is a SMARCA4-deficient cancer or a cancer with decreased expression of SMARCA4 relative to normal SMARCA4 expression.

~~4036. The pharmaceutical composition according to~~ ~~of~~ claim ~~3935~~, wherein the SMARCA4-deficient cancer or the cancer with decreased expression of SMARCA4 relative to normal SMARCA4 expression is lung cancer or non-small cell lung cancer.

~~41. The compound of claim 9, wherein R₁₅ has the chemical structure~~  ~~or~~  ~~, wherein R_{28a} is halogen, optionally substituted alkyl, or fluoroalkyl.~~